Journal of Clinical Pathology and Laboratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Clinical Pathology and Laboratory Medicine (2024) Volume 6, Issue 3

Hepatitis B Virus (HBV) in Clinical Pathology and Laboratory Medicine

Elena Bianchi *

Department of Pathology, University of Sannio, Benevento, Italy

*Corresponding Author:
Elena Bianchi
Department of Pathology, University of Sannio, Benevento, Italy
E-mail: bianchielena@gmail.it

Received:01-June-2024, Manuscript No. AACPLM-24-141966; Editor assigned: 04-June-2024, PreQC No AACPLM-24-141966 (PQ) Reviewed:18-June-2024, QC No. AACPLM-24-141966 Revised:21-June-2024, Manuscript No. AACPLM-24-141966 (R); Published:25-June-2024, DOI:10.35841/aacplm-6.3.211

Citation: Bianchi E. Hepatitis B Virus (HBV) in Clinical Pathology and Laboratory Medicine. J Clin Path Lab Med. 2024;6(3):211

Introduction

Hepatitis B Virus (HBV) is a major public health concern worldwide, particularly affecting hepatology and infectious disease specialties within clinical pathology. This virus is notorious for causing hepatitis B, a spectrum of liver infections ranging from acute to chronic phases, potentially leading to severe complications such as cirrhosis and hepatocellular carcinoma if left untreated. Understanding HBV's pathology, diagnostic methods, management strategies, and ongoing research efforts are crucial for mitigating its impact on global health [1].

HBV is a partially double-stranded DNA virus belonging to the Hepadnaviridae family. Its pathogenesis begins with viral entry into hepatocytes via the NTCP receptor, followed by uncoating and replication of viral DNA in the nucleus [2]. The virus can induce a broad spectrum of clinical outcomes, from asymptomatic carriers to acute hepatitis, chronic hepatitis, liver cirrhosis, and Hepatocellular Carcinoma (HCC). Chronic HBV infection is defined by the persistence of HBsAg (Hepatitis B Surface Antigen) for more than six months, indicating ongoing viral replication and potential liver damage [3].

Accurate diagnosis of HBV infection relies on a combination of serological and molecular techniques. Serological tests detect viral antigens (HBsAg, HBeAg) and antibodies (anti-HBs, anti-HBc) in serum, indicating current infection, immune response, or vaccination status [4]. Molecular assays such as PCR (polymerase chain reaction) are essential for quantifying viral DNA levels (HBV DNA) in serum, guiding treatment decisions and assessing response to therapy. Liver function tests (ALT, AST, bilirubin) complement these tests by indicating the degree of liver inflammation and damage [5].

The management of HBV infection aims to suppress viral replication, prevent liver damage, and reduce the risk of long-term complications [6]. Antiviral therapies such as nucleos(t)ide analogs (e.g., tenofovir, entecavir) inhibit viral DNA polymerase, effectively suppressing HBV replication. Pegylated interferon-alpha can also be used to boost the immune response against HBV. The choice of therapy depends on the patient's Hepatitis B e Antigen (HBeAg) status, HBV DNA levels, liver histology, and the presence of comorbidities [7].

Public health strategies play a crucial role in controlling HBV transmission and improving vaccination coverage. Universal vaccination programs, particularly of infants and high-risk populations, have significantly reduced HBV prevalence in many regions [8]. Screening programs for HBV infection in pregnant women, blood donors, and high-risk groups help identify cases early, enabling timely intervention and prevention of vertical and horizontal transmission [10].

Ongoing research focuses on several fronts to enhance HBV management. This includes understanding viral persistence mechanisms, developing novel antiviral agents with improved efficacy and safety profiles, elucidating host-virus interactions influencing disease outcomes, and exploring immunotherapeutic approaches to achieve functional cure (HBsAg loss with or without seroconversion). Advances in next-generation sequencing and omics technologies are also shedding light on HBV virology and host responses, paving the way for personalized medicine approaches [9].

Conclusion

In conclusion, HBV remains a significant global health burden necessitating continued efforts in prevention, diagnosis, and treatment. Clinical pathology and laboratory medicine play pivotal roles in the comprehensive management of HBV infection through accurate diagnosis, monitoring of disease progression, and guiding therapeutic decisions. With ongoing research and collaborative efforts, the goal of reducing HBV-related morbidity and mortality is within reach, promising better outcomes for affected individuals worldwide.

References

  1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.

    2. Indexed at, Google Scholar , Cross Ref

  2. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99.

    3. Indexed at, Google Scholar , Cross Ref

  3. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.

    4. Indexed at, Google Scholar , Cross Ref

  4. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972-84.

    5. Indexed at, Google Scholar , Cross Ref

  5. Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545-58.

    6. Indexed at, Google Scholar , Cross Ref

  6. Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5(4):a021501.

    7. Indexed at, Google Scholar , Cross Ref

  7. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013 Dec 20;62(10):1-9.

    8. Indexed at, Google Scholar

  8. Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 2023;20(8):524-37.

    9. Indexed at, Google Scholar , Cross Ref

  9. Tang LS, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. Jama. 2018;319(17):1802-13.

    10. Indexed at, Google Scholar , Cross Ref

  10. Revill PA, Tu T, Netter HJ, et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat. Rev. Gastroenterol. Hepatol. 2020;17(10):618-34.

    11. Indexed at, Google Scholar , Cross Ref

Get the App